Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended
	Jun. 30, 2022	Jun. 30, 2015	Dec. 31, 2023	Oct. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Summary of significant accounting policies
Inventory			$ 12,448			$ 3,282
ISBRELA And XPHOZAH Units, Previously Expensed In Period Prior To Commencement Of Capitalization Of Inventory Costs
Summary of significant accounting policies
Inventory			$ 21,800			$ 28,000
Minimum
Summary of significant accounting policies
Estimated useful lives			3 years
Maximum
Summary of significant accounting policies
Estimated useful lives			5 years
AstraZeneca | AZ Termination Agreement
Summary of significant accounting policies
Percentage of royalty revenue		10.00%
Percentage of non royalty revenue		20.00%
Maximum potential payment per agreement		$ 75,000
Aggregate cost of revenue recognized			$ 27,600
Healthcare royalty partners IV, L.P | Licensing revenue
Summary of significant accounting policies
Royalty payments and commercial milestone payments	$ 20,000
Upfront payment	10,000
Payment to be received	$ 5,000			$ 5,000	$ 5,000